Drew Ranieri
Stock Analyst at Morgan Stanley
(0.98)
# 3,964
Out of 5,242 analysts
170
Total ratings
44.57%
Success rate
-12.09%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SIBN SI-BONE | Maintains: Overweight | $20 → $23 | $14.84 | +54.99% | 16 | Dec 2, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $70 → $100 | $79.93 | +25.11% | 14 | Dec 2, 2025 | |
| ATEC Alphatec Holdings | Maintains: Equal-Weight | $16 → $21 | $8.22 | +155.47% | 11 | Nov 10, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $4 → $6 | $2.43 | +146.91% | 4 | Mar 5, 2025 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $317.75 | +40.05% | 9 | Dec 2, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $14.38 | +87.76% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $2.72 | +194.12% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $17.33 | +26.95% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $15.85 | -49.53% | 13 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $75 → $83 | $3.86 | +2,037.31% | 10 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $23.05 | +64.86% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $56.85 | +68.87% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $24.75 | +5.05% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $146.95 | +100.75% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $132.74 | +110.94% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $10.66 | -53.10% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $18.33 | +281.89% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $441.58 | -32.06% | 6 | Apr 25, 2022 |
SI-BONE
Dec 2, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $14.84
Upside: +54.99%
Globus Medical
Dec 2, 2025
Maintains: Overweight
Price Target: $70 → $100
Current: $79.93
Upside: +25.11%
Alphatec Holdings
Nov 10, 2025
Maintains: Equal-Weight
Price Target: $16 → $21
Current: $8.22
Upside: +155.47%
Organogenesis Holdings
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $4 → $6
Current: $2.43
Upside: +146.91%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $317.75
Upside: +40.05%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $14.38
Upside: +87.76%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $2.72
Upside: +194.12%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $17.33
Upside: +26.95%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $15.85
Upside: -49.53%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $75 → $83
Current: $3.86
Upside: +2,037.31%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $23.05
Upside: +64.86%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $56.85
Upside: +68.87%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $24.75
Upside: +5.05%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $146.95
Upside: +100.75%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $132.74
Upside: +110.94%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $10.66
Upside: -53.10%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $18.33
Upside: +281.89%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $441.58
Upside: -32.06%